IBDEI2BO ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39388,1,4,0)
 ;;=4^H40.33X2
 ;;^UTILITY(U,$J,358.3,39388,2)
 ;;=^5005862
 ;;^UTILITY(U,$J,358.3,39389,0)
 ;;=H40.33X3^^153^1921^127
 ;;^UTILITY(U,$J,358.3,39389,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39389,1,3,0)
 ;;=3^Traumatic Glaucoma,Bilateral,Severe Stage
 ;;^UTILITY(U,$J,358.3,39389,1,4,0)
 ;;=4^H40.33X3
 ;;^UTILITY(U,$J,358.3,39389,2)
 ;;=^5005863
 ;;^UTILITY(U,$J,358.3,39390,0)
 ;;=H40.33X4^^153^1921^124
 ;;^UTILITY(U,$J,358.3,39390,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39390,1,3,0)
 ;;=3^Traumatic Glaucoma,Bilateral,Indeterminate Stage
 ;;^UTILITY(U,$J,358.3,39390,1,4,0)
 ;;=4^H40.33X4
 ;;^UTILITY(U,$J,358.3,39390,2)
 ;;=^5005864
 ;;^UTILITY(U,$J,358.3,39391,0)
 ;;=H21.233^^153^1921^26
 ;;^UTILITY(U,$J,358.3,39391,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39391,1,3,0)
 ;;=3^Degeneration of Iris,Bilateral
 ;;^UTILITY(U,$J,358.3,39391,1,4,0)
 ;;=4^H21.233
 ;;^UTILITY(U,$J,358.3,39391,2)
 ;;=^5005189
 ;;^UTILITY(U,$J,358.3,39392,0)
 ;;=H40.61X1^^153^1921^40
 ;;^UTILITY(U,$J,358.3,39392,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39392,1,3,0)
 ;;=3^Drug-Induced Glaucoma,Right Eye,Mild Stage
 ;;^UTILITY(U,$J,358.3,39392,1,4,0)
 ;;=4^H40.61X1
 ;;^UTILITY(U,$J,358.3,39392,2)
 ;;=^5005907
 ;;^UTILITY(U,$J,358.3,39393,0)
 ;;=H40.013^^153^1921^59
 ;;^UTILITY(U,$J,358.3,39393,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39393,1,3,0)
 ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,39393,1,4,0)
 ;;=4^H40.013
 ;;^UTILITY(U,$J,358.3,39393,2)
 ;;=^5005726
 ;;^UTILITY(U,$J,358.3,39394,0)
 ;;=H40.012^^153^1921^60
 ;;^UTILITY(U,$J,358.3,39394,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39394,1,3,0)
 ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Left Eye
 ;;^UTILITY(U,$J,358.3,39394,1,4,0)
 ;;=4^H40.012
 ;;^UTILITY(U,$J,358.3,39394,2)
 ;;=^5005725
 ;;^UTILITY(U,$J,358.3,39395,0)
 ;;=H40.011^^153^1921^61
 ;;^UTILITY(U,$J,358.3,39395,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39395,1,3,0)
 ;;=3^Glaucoma Suspect/Open Angle w/ Borderline Findings,Low Risk,Right Eye
 ;;^UTILITY(U,$J,358.3,39395,1,4,0)
 ;;=4^H40.011
 ;;^UTILITY(U,$J,358.3,39395,2)
 ;;=^5005724
 ;;^UTILITY(U,$J,358.3,39396,0)
 ;;=H40.023^^153^1921^84
 ;;^UTILITY(U,$J,358.3,39396,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39396,1,3,0)
 ;;=3^Open-Angle w/ Borderline Findings,Hi Risk,Bilateral
 ;;^UTILITY(U,$J,358.3,39396,1,4,0)
 ;;=4^H40.023
 ;;^UTILITY(U,$J,358.3,39396,2)
 ;;=^5005730
 ;;^UTILITY(U,$J,358.3,39397,0)
 ;;=H40.063^^153^1921^108
 ;;^UTILITY(U,$J,358.3,39397,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39397,1,3,0)
 ;;=3^Primary Angle-Closure w/o Glaucoma Damage,Bilateral
 ;;^UTILITY(U,$J,358.3,39397,1,4,0)
 ;;=4^H40.063
 ;;^UTILITY(U,$J,358.3,39397,2)
 ;;=^5005746
 ;;^UTILITY(U,$J,358.3,39398,0)
 ;;=H40.243^^153^1921^113
 ;;^UTILITY(U,$J,358.3,39398,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39398,1,3,0)
 ;;=3^Residual Stage Angle-Closure Glaucoma,Bilateral
 ;;^UTILITY(U,$J,358.3,39398,1,4,0)
 ;;=4^H40.243
 ;;^UTILITY(U,$J,358.3,39398,2)
 ;;=^5005845
 ;;^UTILITY(U,$J,358.3,39399,0)
 ;;=H40.043^^153^1921^121
 ;;^UTILITY(U,$J,358.3,39399,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39399,1,3,0)
 ;;=3^Steroid Responder,Bilateral
 ;;^UTILITY(U,$J,358.3,39399,1,4,0)
 ;;=4^H40.043
 ;;^UTILITY(U,$J,358.3,39399,2)
 ;;=^5005738
 ;;^UTILITY(U,$J,358.3,39400,0)
 ;;=B02.39^^153^1922^10
 ;;^UTILITY(U,$J,358.3,39400,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39400,1,3,0)
 ;;=3^Herpes Zoster Eye Disease NEC
 ;;^UTILITY(U,$J,358.3,39400,1,4,0)
 ;;=4^B02.39
